Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
1
8%
Ph phase_3
1
8%
Ph phase_2
9
75%
Ph not_applicable
1
8%

Phase Distribution

1

Early Stage

9

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
9(75.0%)
Phase 3Large-scale testing
1(8.3%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(6)
Terminated(4)
Other(2)

Detailed Status

Completed6
Terminated2
unknown2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 29 (75.0%)
Phase 31 (8.3%)
N/A1 (8.3%)

Trials by Status

completed650%
terminated217%
unknown217%
withdrawn217%

Recent Activity

0 active trials
Showing 5 of 12
withdrawnphase_2

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

NCT06646016
withdrawnphase_2

Study of Photopheresis in the Treatment of Erythrodermic MF and SS

NCT03563040
terminatedphase_3

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

NCT02524847
terminatedphase_2

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

NCT02322190
completedphase_2

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

NCT00054613
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT06646016Phase 2

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

Withdrawn
NCT03563040Phase 2

Study of Photopheresis in the Treatment of Erythrodermic MF and SS

Withdrawn
NCT02524847Phase 3

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Terminated
NCT02322190Phase 2

Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD

Terminated
NCT00054613Phase 2

Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease

Completed
NCT00054600Phase 2

Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease

Completed
NCT00639717Phase 2

Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant

Completed
NCT00221000Phase 2

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

Completed
NCT00030589Phase 2

Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma

Unknown
NCT00930566Phase 1

Extracorporal Photopheresis Pilot Study

Unknown
NCT00002011Not Applicable

The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex

Completed
NCT00004359Phase 2

Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12